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Bckground/aim: Invasive aspergillosis (IA) is a fatal infection that is difficult to diagnose in immunocompromised patients. In this
study, Aspergillus-specific DNA was searched using real-time PCR (RT-PCR) in serum samples. Galactomannan (GM) and/or beta-Dglucan (BDG) tests were previously performed on these samples for 70 neutropenic patients with hematological malignancy.
Materials and methods: The patients were categorized according to the criteria of the European Organization for Research and
Treatment of Cancer/Mycoses Study Group (EORTC/MSG). Among the patient serum samples, the first positive GM or BDG test
sample and the median sample of GM or BDG test for negative patients were used to detect DNA levels by RT-PCR method (Light
Cycler 480, Roche Molecular Biochemicals, Meylan, France) using a commercial kit (Way2Gene Fungi; Genmar, İzmir, Turkey).
Results: When the proven and probable IA group were considered as real patients, sensitivity of Aspergillus-specific DNA test was 90%,
specificity was 73.3%, positive predictive value was 81.8%, and negative predictive value was 84.6%.
Conclusion: This study found that searching for specific DNA by RT-PCR method has a sensitivity as high as the GM test. Although
specificity was rather low, it was concluded that it can be used jointly with GM and BDG tests after decreasing contamination by severe
laboratory applications.
Key words: Invasive aspergillosis, galactomannan test, beta-D-glucan test, specific DNA

1.Introduction
Aspergillus species are mainly soil saprophytes and
are commonly found in nature. They cause different
clinical situations in humans, ranging from toxicallergic disorders to invasive diseases. Invasive diseases
are the most dangerous, and all cancer patients with
hematological malignancies, patients undergoing bone
marrow and organ transplantation, patients with cystic
fibrosis, and patients with autoimmune and chronic
granulomatosis diseases are at high risk. Sinonasal and
pulmonary infections are the most common forms of
invasive aspergillosis (IA) and may result in disseminated
infection by spreading from these foci (1–3). Its frequency
accounts for 40%–60% of cases (4,5). A. fumigatus is the
predominant etiological agent, followed by A. flavus and
A. terreus (6,7).
* Correspondence: bener@uludag.edu.tr

Early initiation of effective antifungal treatment is
essential for improving the outcomes in infected patients.
Clinical findings are not specific, and conventional
diagnostic methods, such as direct microscopic
examination and cultivation, are not sufficient to detect
the disease. The utility of standard blood cultures for
Aspergillus species is limited because of a high percentage
of false negative results, even in patients with disseminated
aspergillosis. Therefore, new diagnostic approaches, such
as searching for galactomannan (GM) and 1,3-beta-Dglucan (BDG) antigens and specific DNA in samples, came
into question (8).
Galactomannan is a molecule that is present in the
cellular walls of Aspergillus species and can be secreted
extracellularly. Several studies have shown that the
determination of GM in serum, bronchoalveolar lavage
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(BAL) fluid, and other samples by a commercial kit
using the sandwich enzyme immunoassay (EIA) method
(Bio-Rad Laboratories, Marne-La-Coquette, France) is
beneficial for the diagnosis of IA (9–12). The results are
read by a spectrophotometer and expressed as optical
density index. The European Conference on Infections in
Leukaemia (ECIL) has strongly recommended that it be
performed as a screening test in bone marrow transplants,
and in patients with hematological malignancies with high
incidence of IA. An optical density index of >0.7 in a single
sample and of >0.5 in two consecutive samples suggests a
diagnosis of IA (13).
BDG is not specific to Aspergillus species; it is a
component in the cellular walls of many fungi, except
for Cryptococcus neoformans and the fungi of the order
Mucorales (14–19). It is one of the promising nonculturebased early diagnostic tests for the diagnosis of invasive
fungal infections (IFIs). This test is based on the reaction
of BDG with factor G of the horseshoe crab coagulation
cascade, and there are multiple commercial assays available
for BDG antigen detection. The Fungitell assay (Beacon
Diagnostics, Falmouth, MA, USA) is the most utilized in
the United States and Europe. With this assay, at least two
consecutive results greater than 80 pg/mL are optimal for
diagnosis of IFIs (15).
Both GM and BDG tests are now incorporated in the
diagnosis of probable IFIs in patients with appropriate
host and clinical factors, as defined by the revised
European Organization for Research and Treatment of
Cancer/Mycoses Study Group (EORTC/MSG) criteria
(20). The major limitation of these tests is their variable
performance characteristics, which are influenced by the
prevalence of the disease, the testing strategy used, age,
underlying condition, concomitant therapy with certain
antimicrobials, and even food consumption (8,21).
Another approach that can be used in the diagnosis of
IA involves searching for Aspergillus-specific DNA due to
its advantages, such as the sensitivity and rapid availability
of the results. Although searching for Aspergillus-specific
DNA has been subject to numerous studies, it was not
included in the EORTC/MSG diagnostic criteria (20,22–
30). The main concern about the molecular detection of
IA is the lack of standardization and validation (8). In
research, various samples, extraction methods, primary
probes, and polymerase chain reaction (PCR) formats
were used, all of which are factors that can potentially
affect the results (8,21,31).
In this study, Aspergillus DNA was searched using realtime PCR (RT-PCR) in stored serum samples, in which
GM and/or BDG results were previously determined for 70
neutropenic patients with hematological malignancy. We
aimed to compare the diagnostic values of these tests and
provide new data for the literature. The rapid, sensitive, and
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high-throughput properties of PCR testing for diagnosing
IA prompted us to investigate its performance.
2.Materials and methods
A total of 70 adult patients, who were followed at the
Hospital Hematology Clinic of Uludağ University,
were included in the study. None received mold active
prophylaxis. The inclusion criteria were the presence of
risk factors for IA (neutropenia is defined as an absolute
neutrophil count below 0.5 × 109/L, recent or current use
of immunosuppressive agents or corticosteroids, and/or
persistent fever under broad-spectrum antibiotherapy).
Clinical data and microbiological and radiological results
were reviewed to classify cases according to the EORTC/
MSG 2008 criteria. Proven IFI requires that a fungus
be detected by histological analysis, culture of a tissue
specimen, or sterile body fluid taken from a site of the
disease. Probable IFIs require the presence of a host factor,
a clinical criterion, and a mycological criterion. Cases that
meet the host factor criteria and a clinical criterion, but
not the mycological criteria, are considered possible IFIs.
(20).
Stored serum samples (–80 °C) of the study group were
used, and these were taken twice a week. Among these
samples, the first GM or BDG positive sample and the
median sample of GM or BDG for serially negative patients
were used to detect DNA level with the RT-PCR (Light
Cycler 480 Instrument; Roche Molecular Biochemicals,
Meylan, France) method (25). DNA extraction from the
samples was carried out using the ZR Fungal/Bacterial DNA
MiniPrep Kit (Zymo Research Corp., Irvine, CA, USA),
according to the recommendations of the manufacturer.
The presence of Aspergillus DNA was detected using
a commercial kit (Way2 Gene Fungi; Genmar, İzmir,
Turkey). In accordance with the recommendations of
the manufacturer, 15 µL of enzyme and primary-probe
mixture (LightCycler 480 Probes Master; Roche Molecular
Biochemicals) was mixed with 5 µL of extracted DNA and
distributed to 96-well plates (LC480 96-well plate white;
Roche Molecular Biochemicals). The denaturation was
achieved with 10 min of preincubation at 95 °C. After
preprocessing, the device was set to 45 cycles of 5 s at 95 °C,
10 s at 55 °C, and 20 s at 72 °C, and distilled water was used
as a negative control. Before cycle 40, the samples in which
exponential fluorescent increase was detected compared to
the negative control were considered as positive (25–28).
As positive standards were not used, quantification of
DNA amount was not performed, and an internal control
was used as the PCR control.
Results of direct microscopic examination and
cultivation of sputum, BAL, bronchial lavage (BL), and
tracheal aspirate (TAS) were evaluated retrospectively
from the laboratory records. Growth in all samples with
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positive direct microscopy was considered significant,
whereas in cases with negative microscopy, growth in
more than one sample was required for significance (32).
GM (Platelia Aspergillus) and BDG (Fungitell assay)
results of the patient group were obtained from the
laboratory records. No patient with positive BDG was
suspected of having PCP and candidemia. Optic density
(OD) index of ≥0.5 for GM and levels of ≥80 pg/mL for
BDG in two consecutive serum samples obtained from a
patient were considered positive.
Cases were grouped as proven, probable, possible, and
non-IA according to EORTC/MSG criteria using direct
microscopic examination, cultivation, and GM and BDG
results. The specificity, sensitivity, positive predictive value
(PPV), and negative predictive value (NPV) of tests were
calculated according to these groups (20).
We investigated the results using SPSS 20 (IBM Corp.,
Armonk, NY, USA).
3. Results
In this study, 57 of 70 neutropenic patients with
hematological malignancy had clinical findings (lower
or upper respiratory tract symptoms such as cough, chest
pain, hemoptysis, dyspnea, nasal discharge, stuffiness, and
epistaxis; lower or upper respiratory physical examination
findings such as pleural rub, eschar of nasal mucosa,
periorbital swelling, and black necrotic lesions; lower
or upper respiratory imaging findings such as dense,
well-circumscribed lesions with or without a halo sign,
air-crescent sign, cavity or erosion of sinus walls, and
extension of infection to neighboring structures) of IA,
while there were no clinical findings in 13 patients. Positive
histopathology, wet-smear examination, and culture in 6
(10.5%) biopsy specimens and 15 (26.3%) respiratory tract
samples (sputum, BAL) were obtained from patients with
clinical findings. The Aspergillus species that were isolated
from 21 patients (36.8%) are summarized in Table 1.
Serial galactomannan antigen screening was done
in all patients in the study group. It was positive in two
consecutive serum samples in 18 of 21 (85.7%) patients
who were direct microscopy- and culture-positive.
Bronchoscopy was performed in the remaining three
patients with negative serum GM levels, since clinical
findings and imaging suggested IA, and both Aspergillus
growth and GM positivity was detected in BAL samples
(Table 1). Serum GM positivity was detected in 18
symptomatic patients whose samples did not display
any growth, whereas no positivity was noted in patients
without clinical findings (Table 1). In Table 2, GM results
and culture outcomes are compared in 57 IA-symptomatic
patients.
BDG was screened in a total of 46 patients, 35 with
clinical findings and 11 without clinical findings. BDG

could not be analyzed in patients who had growth in
biopsy samples. BDG was positive in 8 of 12 (66.7%)
patients who had growth in respiratory tract samples
(Table 1). While growth and GM positivity were detected
in all BAL samples obtained from 4 patients with negative
serum BDG level, BAL BDG was positive in 3 samples.
BDG was positive in 5 more patients who had no growth
but displayed clinical findings. GM was also positive in 4
of these patients, while one remained negative (Table 1).
Positivity in terms of direct microscopic examination and
cultivation in patients (35 patients) with clinical findings
who underwent both GM and BDG tests are shown in
Table 3.
Specific DNA was found in the samples of all 6 patients
in whom tissue diagnosis was made and was positive
in 12 of 15 patients with growth in the respiratory tract
samples. In two patients who remained negative, GM and
BDG were positive, and in one patient both GM and BDG
and the median serum sample specific DNA was negative,
although A. terreus growth occurred in the BAL sample.
While GM and BDG remained negative in a patient
who had A. fumigatus growth, only DNA was detected
(Table 1). DNA was positive in 18 of 19 patients who had
clinical findings and GM and/or BDG positivity but no
growth. DNA positivity was detected in 4 (23.5%) of 17
symptomatic patients who had no growth and remained
GM/BDG-negative. Furthermore, DNA positivity was
detected in 4 (30.8%) of 13 patients without clinical
findings (Table 1). Since there was no significant difference
between these percentages (P = 0.7; χ2 test), positivity
found in the possible IA group was not considered in favor
of IA. GM/BDG, DNA, and culture positivities of the 57
symptomatic patients are compared in Table 4.
The grouping of patients according to the EORTC/
MSG criteria is shown in Table 5 (20). DNA findings were
not included in the grouping, since DNA detection was not
among the criteria. When proven and probable IA patients
(40 patients) were considered as the real patient group,
sensitivity of DNA detection was 90%, specificity was
73.3%, positive predictive value was 81.8%, and negative
predictive value was 84.6%.
4. Discussion
Aspergillus species are common saprophytic, heat-resistant
molds that grow in various environmental conditions.
Although hundreds of Aspergillus spores are inhaled every
day, disease rarely occurs. Various clinical situations can
develop, ranging from allergic diseases in atopic individuals
to invasive diseases in immunosuppressed people (1,2,4).
The most important challenge is the difficulty in diagnosis
of invasive diseases. Thus, a comparison of various
methods used in the diagnosis of IA was carried out in this
study.
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Table 1. Direct microscopic examination, culture, GM, BDG, and DNA test results of the study patients.
IA categories
(number of patients)

Specimen type
(number of specimens)

Direct microscopic
examination

Aspergillus species

No. of patients with
positive GM

No. of patients with
positive BDG

No. of patients with
positive DNA

Proven IA (6)

Lung biopsy tissue (3)
Nasal biopsy tissue (2)
Pleural fluid (1)

Positive (6)

A. flavus (5)
A. fumigatus (1)

6

Not done

6

Probable IA (5)

Sputum (2 P)
BAL (2 P)
Sputum (1 N)

Positive (4)
Negative (1)

A. flavus (3)
A. terreus (1)
A. fumigatus (1)

5

5

5

Probable IA (3)

TAS (1)
BAL (1)
Sputum (1)

Positive (3)

A. flavus (2)
A. fum + A. flav (1)

3

Not done

3

Probable IA (2)

BAL (1)
BAL (1)

Positive (1)
Negative (1)

A. fum + A. ter (1)
A. flavus (1)

2

2

N

Probable IA (2)

BAL (2)

Positive (2)

A fumigatus (1)
A. flavus (1)

2

N

2

Probable IA (1)

BAL (1)

Positive (1)

A. niger (1)

N

1

1

Probable IA (1)

BAL (1)

Positive (1)

A. fumigatus (1)

N

N

1

Probable IA (1)

BAL (1)

Negative (1)

A. terreus (1)

N

N

N

Probable IA (4)

N

N

4

4

4

Probable IA (2)

N

N

2

N

2

Probable IA (1)

N

N

N

1

1

Probable IA (11)

N

N

11

Not done

11

Probable IA (1)

N

N

1

Not done

N

Possible IA (13)

N

N

N

N

N

Possible IA (1)

N

N

N

Not done

1

Possible IA (3)

N

N

N

N

3

Non-IA (8)

N

N

N

N

N

Non-IA (1)

N

N

N

Not done

N

Non-IA (3)

N

N

N

N

3

Non-IA (1)

N

N

N

Not done

1

TOTAL (70)

21 specimens

Aspergillus spp. (21)

36

13

44

Positive (18)

IA: invasive aspergillosis; BAL: bronchoalveolar lavage; GM: galactomannan; BDG: beta-D-glucan; N: negative.

Table 2. Comparison of culture and GM results in symptomatic patients.
DME and culture (+)

DME and culture (–)

Total

GM (+)

18

18

36 (63.2%)

GM (–)

3

18

21

Total

21 (36.8%)

36

57

DME: direct microscopic examination; GM: galactomannan.
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Table 3. Culture positivity in samples of symptomatic patients who underwent GM and BDG tests (35 samples).
DME and culture (+)

DME and culture (–)

Total

GM and BDG (+)

7

4

11

GM (+) BDG (–)

2

2

4

GM (–) BDG (+)

1

1

2

GM and BDG (–)

2

16

18

Total

12

23

35

DME: direct microscopic examination; GM: galactomannan; BDG: beta-D-glucan.
Table 4. GM/BDG, DNA, and culture positivity in symptomatic patients.
DME and culture (+)

DME and culture (–)

Total

GM/BDG (+) DNA (+)

17

18

35

GM/BDG (+) DNA (–)

2

1

3

GM/BDG (–) DNA (+)

1

4

5

GM/BDG (–) DNA (–)

1

13

14

Total

21

36

57

GM: galactomannan; BDG: beta-D-glucan.
Table 5. Grouping of the patients according to EORTC/MSG criteria and positivity data.
Patient group

Clinical finding

Histopathology (+)

DME and culture (+)

GM (+)

BDG (+)a

Proven IA (6)

6

6

6

6

-b

Probable IA (34)

34

0

15

30

13c

Possible IA (17)

17

0

0

0

0d

Non-IA (13)

0

0

0

0

0e

Total (70)

57

6

21

36

13

: Beta-D-glucan (BDG) was analyzed in a total of 46 patients; b: not analyzed, c: analyzed in 19 patients; d: analyzed in 16 patients;
: analyzed in 11 patients.
DME: direct microscopic examination; GM: galactomannan.
a
e

Microscopic examination of patient samples and
cultivation are indispensable classical diagnostic
methods. Although blood and tissue biopsy cultures are
the most valuable samples in the diagnosis of invasive
diseases, the sensitivity of blood samples is rather low
(<5%), and obtaining tissue sample is difficult due to
thrombocytopenia. In this study, diagnosis could be
made in only 6 of 57 symptomatic patients (10.5%) by
tissue biopsy. Therefore, most samples used for diagnosis
were obtained from lower and upper respiratory tract
specimens. In the diagnosis of IA in neutropenic
patients with hematologic malignancy, sensitivity of
respiratory tract samples ranged between 15% and

77%, whereas positive predictive value was considered
as approximately 70%–80% (33–39). In this study,
growth occurred in 26.3% of the respiratory samples,
which is mostly BAL and considered significant, since
direct microscopic examination was also revealed to be
positive in 85.7%.
The most common species isolated in IA cases is A.
fumigatus, followed by A. flavus (4). A. flavus accounted
for more than half of the isolated strains in our study.
However, this study was not an epidemiological trial, and,
additionally, high prevalence of A. flavus was mentioned
in other studies in which regional differences may have
occurred (40).
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Research has shown that the EIA kit used for searching
for GM antigen has a wide range of sensitivity at 29%–
100% (9). The most important reason for this difference
is searching within various types of patient groups. In
deeply neutropenic patients with hematologic malignancy,
sensitivity is as high as 90%–100%. Similarly, in this study,
85.7% of 21 patients with positive culture results also
showed GM positivity. Sensitivity is diminished in other
cancer patients, solid organ transplants, cases with chronic
aspergillosis, and local infections. It has been suggested
that blood neutrophils clear GM antigen and decrease the
sensitivity of the test in these patient populations (41,42).
In the literature, the sensitivity of BDG test has been
reported as 70%–100% and specificity as 75%–90%
(14–19). In this study, 66.7% of 21 patients with positive
culture results also showed BDG positivity, slightly lower
than in other studies. However, lack of BDG testing in all
samples, especially those with histopathologic diagnosis,
was considered as a limitation, and low sensitivity was
attributed to this.
As mentioned above, GM and BDG tests were included
in the EORTC/MSG criteria for use in the diagnosis of IA.
In this study, 40 symptomatic patients were identified as
having proven and probable IA by including GM and/or
BDG positivity. In contrast, 21 patients were evaluated
as having proven and probable IA using only direct
microscopic examination and culture. It was clearly
demonstrated that by adding new methods to existing
ones and by using multiple methods simultaneously, the
chance of diagnosis would increase. Recently, Hoenigl et
al. (43) investigated 78 patients at risk for IA and found
that Aspergillus PCR, GM, and lateral flow device tests are
the most useful methods for diagnosing the disease by
using BAL. They also showed that the combination of PCR
and GM tests allows for sensitive and specific diagnosis of
IA, which is in concordance with our study.
In this study, the sensitivity of Aspergillus DNA was
90% and the specificity in patient sera was 73.3%. It is
possible to find numerous studies that compare GM,
BDG, and specific DNA tests (22–30). In most of these
studies, standard methods were used for GM and BDG,
whereas different DNA search methods were used, as
mentioned above. Therefore, it is possible to reach various
results and new data that can contribute to the literature
that underpins this study. In these comparative studies,
sensitivity of different formats of PCR methods ranged
between 41% and 100%. The highest levels of sensitivity
were achieved by using >1 mL of whole blood samples
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and RT-PCR. In this study, however, 90% sensitivity was
captured with the RT-PCR method using a 200-µL serum
sample. We suggest that rather than type and amount of
sample or extraction method used, primary probes and
PCR format are more important in terms of sensitivity.
Similar to sensitivity, various PCR formats had a specificity
of 40%–100% (22–30). Nevertheless, due to decrease in
contamination, highest specificity was achieved by RTPCR. In this study, DNA was searched in samples where
the previous analyses were performed for GM and BDG.
Thus, this might be the reason for the low specificity
(73.3%) obtained in this study compared to other studies
that also used RT-PCR. There is a risk of contamination
in each step, including obtaining blood samples from
patients, transferring, and processing. In order to decrease
false positivity, rigid laboratory regulations should be
followed in all PCR test formats.
An experimental study from Turkey that compared the
diagnostic performance of GM, BDG, and PCR showed
that excellent specificity and PPV (both 100%) were
obtained by PCR, although decreased sensitivity (41.2%)
and NPV (16.7%) were disappointing (44). The study
was an experimental rat study and perhaps the decrease
in sensitivity findings is due to host differences. There is
only one clinical study from Turkey about the diagnostic
performance of GM and PCR. This study found that
sensitivity values obtained by a commercial real-time
PCR kit and GM were 65% and 23%, respectively. Aslan
et al. (45) argued that the sensitivity of the PCR kit may be
increased by using GM in combination in diagnosis. This
finding is in accordance with our study, and the sensitivity
reached by combining PCR and GM (90%) is higher than
that obtained in studies from Turkey by using either GM
(60%) or BDG (66%) (46,47).
In conclusion, despite these improvements, IA is still
a disease that is difficult to diagnose. There is no single
method for reaching a complete diagnosis. However,
combined use of diagnostic tests can improve sensitivity.
Although the low number of patients without IA is
a limitation for this study, successful sensitivity and
specificity were achieved by RT-PCR, and this can be
used alongside GM and BDG tests after decreasing the
contamination by tight laboratory applications.
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